You are most concerned about extrapyramidal symptoms (EPS) if your patient is on which of the following? (Select all that apply.)

Choice A reason: First-generation antipsychotics are strongly associated with EPS due to potent dopamine blockade in the nigrostriatal pathway. Choice B reason: Aripiprazole is an atypical antipsychotic with partial dopamine agonist activity. It has a lower risk of EPS compared to first-generation agents. Choice C reason: Haloperidol is a high-potency first-generation antipsychotic with a high risk of EPS, including dystonia, akathisia, and parkinsonism. Choice D reason: Chlorpromazine is a low-potency first-generation antipsychotic that also carries a risk of EPS, though less than haloperidol. Choice E reason: Olanzapine is an atypical antipsychotic with a lower risk of EPS. Its side effects are more commonly metabolic, such as weight gain and diabetes.